Get started

Bayer

SWING IDEA - BAYER CROPSCIENCEBayer CropScience , a global leader in agricultural science, is exhibiting technical indicators that suggest a promising swing trading opportunity. Reasons are listed below : 6500 Resistance Breakout : The 6500 level has been a significant resistance zone. The price is now breaking out above this level, indicating strong bullish momentum. Breaking 4+ Year Consolidation Phase : The stock is breaking out of a long consolidation phase that lasted over 4 years, signaling a potential new bullish trend. Strong Bullish Marubozu Candle on Weekly Timeframe : The recent formation of a bullish marubozu candle on the weekly chart indicates strong buying pressure and suggests potential for further upward movement. Bounced Back from Golden Fibonacci Zone : The stock has bounced back from the golden Fibonacci retracement level (0.618), a key area where prices often rebound, indicating potential for an upward move. Trading Above 50 and 200 EMA on Weekly Timeframe : The stock is trading above both the 50-week and 200-week exponential moving averages (EMA), reinforcing the bullish sentiment and providing strong support levels. Trading at All-Time High : The stock is trading at its all-time high, suggesting strong market confidence and potential for further gains. Target - 7670 // 8700 Stoploss - weekly close below 5600 DISCLAIMER - Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services. @visionary.growth.insights
NSE:BAYERCROPLong
by Visionary_Growth_Insights
Bayer (BAYN): End of a long 9-year correctionBayer (BAYN): XETR:BAYN Upon request from one of our members, we're taking a closer look at Bayer AG. We believe that we are still in an overarching Wave II. This wave finds its last true support at the 88.2% retracement level at €24.51. Falling significantly below this level would likely lead us to see a 100% retracement down to €8.48, which would be severe for a company like Bayer, considering its all-time high was at €144. Observing the chart on a 2-day basis, we note that the Wave 5 extension falls into the zone between 50% and 61.8%, which also includes the 88.2% level. This truly is the last turning point Bayer might have.
XETR:BAYNLong
by freeguy_by_wmc
1
Bayer (BAYN): Is the Bottom Finally Here?Since our initial analysis in November, Bayer's stock has experienced a 40% pullback. Despite missing our limit order by 2%, we have decided to enter the market now and plan to make additional purchases if the price drops further. The stock has held around the 88.2% Fibonacci retracement level. We are currently within the 50-61.8% Fibonacci extension zone for Wave 5, which aligns with our bottom outlook. Our entry strategy involves making an initial purchase now, acknowledging the recent support levels. We plan to add to our position with multiple entries if the price drops further. Our stop-loss is set wide, at an additional 44% below our entry price, to accommodate potential volatility. This is considered a long-term swing trade, with an expectation of significant upward movement once the bottom is confirmed. This could be a knife catch here so please don't cut yourself too deep.
XETR:BAYNLong
by freeguy_by_wmc
If Germany is the sick man of Europe. #Bayer looking deathlyThe #EU is Marxist, Socialist, and is involved in Price setting That didn't work out too well for USSR as economic powerhouse and so too we see the once great German economy being brought to it's knees. It is being de-industralized and being brought down in a great economic levelling of the union Such a shame Bayer Pharmaceutical is arguably a company we could do without .. so this chart does not upset me too much ... But it is major component of the #DAX and highlights the economic pain that Germany may indeed go through in the next recession.
XETR:BAYNShort
by BallaJi
7
Bayer Cuts Dividends to Reduce DebtIn a strategic move to tackle its mounting debt and enhance financial flexibility, Bayer ( OTC:BAYRY ), the German pharmaceutical giant, has announced a significant shift in its dividend policy. The decision, though met with mixed reactions from investors and analysts, underscores the company's commitment to addressing its pressing financial challenges. Facing High Debt and Challenging Cash Flow: Bayer's ( OTC:BAYRY ) decision to amend its dividend policy stems from a pressing need to mitigate its high debt burden and grapple with a challenging free cash flow situation. Chief Executive Bill Anderson emphasized the company's priority to reduce debt and increase flexibility, acknowledging the necessity of the amended dividend policy in achieving these objectives. A Drastic Reduction in Dividends: The scale of the dividend reduction is striking. From 2.40 euros per share in the previous year, Bayer ( OTC:BAYRY ) now proposes a mere 0.11 euro dividend for 2023. This substantial cut reflects the severity of the financial constraints Bayer is contending with and underscores the urgency with which it seeks to address them. Analyst Insights and Investor Reactions: Analysts at Jefferies have characterized Bayer's move as emblematic of the extensive operational and financial challenges confronting the company. They emphasize the need for further significant strategic actions to rectify the balance sheet and restore investor confidence. Investor reactions have been mixed, with some expressing understanding of the company's predicament, while others voice concerns about the implications for shareholder returns and the long-term health of the business. Strategic Imperatives: Job Cuts and Potential Breakup: Bayer's ( OTC:BAYRY ) dividend policy amendment follows a series of strategic maneuvers aimed at stabilizing its financial position and reigniting growth. In January, the company announced job cuts, signaling a commitment to streamline operations and reduce costs. Moreover, Bayer ( OTC:BAYRY ) has been exploring options to potentially dismantle its diverse portfolio, which includes prescription drugs, consumer health products, crop chemicals, and seeds. This strategic evaluation underscores the company's willingness to undertake bold measures to revitalize its performance and buoy its beleaguered share price. Conclusion: Bayer's ( OTC:BAYRY ) decision to revise its dividend policy represents a pivotal moment in its ongoing efforts to navigate choppy financial waters. As the company grapples with high debt, challenging cash flow dynamics, and analyst scrutiny, its strategic imperatives underscore a commitment to reshaping its business for sustained success. The road ahead may be fraught with challenges, but Bayer's ( OTC:BAYRY ) willingness to confront them head-on signals a determination to emerge stronger and more resilient in the face of adversity.
OTC:BAYRYLong
by DEXWireNews
Bayer: Down the hatch! 🍺After Bayer's stock recently tried to break through the support level of €39.91, it has now made another attempt. Whether the stock succeeds in sustainably breaking below this support level - as envisaged in our primary scenario - or whether it needs further impetus in the form of a corrective upward move is irrelevant for the further course of our expectations. We therefore fully expect a sell-off below this level, as we expect the low of the major wave (II) correction underway since 2015 to be around the 78.60 retracement at €30.84. Only once this low is in place do we see Bayer shares making sustainable gains again.
XETR:BAYNShort
by MarketIntel
1
Why Bayer Stock is a Great Long-Term Investment OpportunityBayer AG is a German multinational pharmaceutical and life sciences company founded in 1863. The company is headquartered in Leverkusen, Germany, and employs over 100,000 people worldwide. Bayer's core business areas are human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals, and biotechnology products. Bayer stock is a great long-term investment opportunity for several reasons. The first one is that its stock has created a strong weekly demand level located at around 49 euros per share. This should be enough reason to buy Bayer AG stock shares. Secondly, the company has a strong history of financial stability and profitability. In addition, Bayer has a diversified product portfolio with exposure to many different industries. Bayer is committed to innovation and has a strong R&D pipeline. Bayer AG is a publicly traded company with shares that trade on the Frankfurt Stock Exchange, and the company has a market capitalization of over €51 billion. The company's stock has not performed well in recent years, losing more than 70% of its value since up more than 50% since 2016. It's now a great opportunity to buy shares of Bayer AG stock. There is a lot of profit potential with room to reach €88 per share and higher.
XETR:BAYNLong
by AlfonsoMoreno
Bayer continues to hold back the bulls.Bayer AG - 30d expiry - We look to Sell at 54.48 (stop at 56.11) Daily signals are bearish. 54.50 continues to hold back the bulls. Bespoke resistance is located at 54.50. Preferred trade is to sell into rallies. The bearish engulfing candle on the daily chart is negative for sentiment. Our profit targets will be 50.41 and 49.41 Resistance: 52.00 / 53.20 / 54.50 Support: 49.50 / 48.50 / 47.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
XETR:BAYNShort
by Saxo
Bayer AG at key supportBayer AG Short Term We look to Buy at 56.39 (stop at 54.46) Trading within a Bullish Channel formation. The medium term bias is for higher levels but intraday signals are mixed. Previous support located at 56.00. Bullish divergence can be seen on the daily (the chart makes a lower low while the oscillator makes a higher low), often a signal of exhausted bearish momentum, or at least a correction higher. Further upside is expected although we prefer to set longs at our bespoke support levels at 56.00, resulting in improved risk/reward. Our profit targets will be 61.39 and 65.99 Resistance: 66.00 / 70.00 / 110.00 Support: 56.00 / 50.00 / 43.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
XETR:BAYNLong
by Saxo
Bayer AG (BAYN.de) bullish scenario:The technical figure Channel Down can be found in the German company Bayer AG (BAYN.de) at daily chart. Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds, and biotechnology products. The company is a component of the Euro Stoxx 50 stock market index. The Channel Down has broken through the resistance line on 12/01/2021, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 49 days towards 54.270 EUR. Your stop loss order according to experts should be placed at 43.905 EUR if you decide to enter this position. Bayer AG on Monday struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen its cell and gene therapy development efforts. Unlisted U.S. biotech firm Mammoth will initially receive $40 million from Bayer plus potential milestone payments of more than $1 billion contingent on scientific and commercial achievements. The initial focus of the collaboration will be liver-based diseases, the companies said in a joint statement on Monday. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
XETR:BAYNLong
by legacyFXofficial
BAYN: Long (end of cycle + support)Hello everyone!!! Bayer AG at the channel support. There is hope for the end of the bearish trend that began in 2015. Additionally, according to the cyclical analysis, we can see the completion of a cycle of 1610 days (or 230 weeks, or 4.5 years). The cycle was repeated 7 times: of which 5 times there was an increase in the share price and 2 times - a fall. Therefore, this time too, we can expect the price to rise at least to the slope and horizontal resistance lines - about € 79 or 70% = take profit. My stop loss is set at € 42.610 (about -12% and 3% below the last local low). As for the indicators, the background is bullish. However, there was a huge bullish gap in 1996 and it has not been closed until now .... I plan to increase my position using the pyramiding method. Not a recommendation, not advice. I wish everyone a lot of profit !! PS Bayer AG - is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals, seeds and biotechnology products. The company is a component of the Euro Stoxx 50 stock market index. Werner Baumann has been CEO since 2016. Founded in Barmen in 1863 as a dyestuffs factory, Bayer's first and best-known product was aspirin. en.wikipedia.org
XETR:BAYNLong
by Dr_Chester
1
Bayer - bullishThis is an update of the charted idea posted on March 13, 2021. The bullish crossover of the 50MA coming up above the 200MA has now happened. The price remains above the green Ichimoku cloud (positive). The Heikin Achi candlestick are small with long wicks on either side, indicating some indecision regarding direction. This could still go on for a while. In the short term, based on the positive sentiment but with the lack of momentum behind it, price could make a swing lower and then break the higher resistance zone (red box). Possible target shown in blue. Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Bayer hasn't had the easiest of times, with the price in decline since all time highs in 2015. Keen to know what others think. Please leave a comment or link to your own ideas! Charts are for information purposes only. Not trade suggestions. DYOR (Do your own research) - act responsibly with your money.
XETR:BAYNLong
by BradtNom
Bayer pharmaceutical stock long term buy opportunityBayer stock is a life science company trading on the German stock exchanges with the symbol BAYN. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and speciality therapeutics, especially in the areas of cardiology, oncology, gynaecology, haematology and ophthalmology, as well as radio-pharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter. Bayer AG stock is a German company trading in the German Stock Exchange. It is one of the biggest and most important pharmaceutical companies in the world. I doubt that you’ve never heard from Bayer AG, because its products range from the famous Aspirin to even “more popular” Viagra 🙂 Now, I believe you are probably smiling and remembering this company 🙂 Before starting to write this blog post on Bayer, I googled the company name to try and find some extra information I could add, that would either support or negate the strong rally we are expecting on this particular pharmaceutical German stock.
XETR:BAYNLong
by AlfonsoMoreno
BAYER Trade Plan Please don't forget to FOLLOW, LIKE, and COMMENT ... If you like my analysis:) Trade Safe - Trade Well Regards, Michael Harding 😎 Chief Technical Strategist @ LEFTURN Inc. RISK DISCLAIMER Information and opinions contained with this post are for educational purposes and do not constitute trading recommendations. Trading Forex on margin carries a high level of risk and may not be suitable for all investors. Before deciding to invest in Forex you should consider your knowledge, investment objectives, and your risk appetite. Only trade/invest with funds you can afford to lose.
XETR:BAYNShort
by Michael_Harding
When it's over? #Bayer #BAYN #tradingviewBayer AG is still in a correction phase since April 2015. An important support line is at EUR 44.10. This line must hodl! Should this be broken on a weekly or even monthly basis with a closing price below it, the range of approx. 38 Euro would be the next support zone. A closing below 38 Euro, a down move to 20-22 Euroarea would not surprise. At 21.62 Euro, the potential wave C would be 1.618 times longer than the wave movement A. Nothing new since first analysis @ Tradingview 2018. Interested parties in Bayer shares should wait further, if necessary, at least until the Monsanto process in California is over. Straight the coming days/weeks might become therefore interesting whether already now a trend reversal can be caused or as described above a further sales takes place. I set my alarm clocks. After 2018 and 2019 it is now the third long term analysis of Bayer here at TradingView. Best regards from Hannover Stefan Bode
XETR:BAYN
by StefanBode